Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Continental AG Shares Jump After Q1 Profit Beats Expectations 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
Anthropic Secures $1.5B AI Venture Backed by Wall Street Giants, Shaking Software Sector 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
EMERYVILLE, Calif., May 04, 2018 -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it will report its financial results for the first quarter ended March 31, 2018, after the market close, and will host a corporate update conference call and webcast on Wednesday, May 9, 2018, at 4:30 PM Eastern Time.
Conference Call Details
Wednesday, May 9th @ 4:30pm Eastern Time/1:30pm Pacific Time
| Toll Free: | 866-548-4713 |
| International: | 323-794-2093 |
| Conference ID: | 7186111 |
| Webcast: | http://public.viavid.com/index.php?id=129538 |
| Replays, available through May 23rd | |
| Domestic: | 844-512-2921 |
| International: | 412-317-6671 |
| Replay PIN: | 7186111 |
About Zogenix
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
CONTACT:
Investors:
Andrew McDonald
Founding Partner, LifeSci Advisors LLC
646-597-6987
[email protected]
